A Phase II Study of Cabozantinib (XL184) in Patients With Advanced/Metastatic Urothelial Carcinoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 01 Feb 2018
At a glance
- Drugs Cabozantinib (Primary)
- Indications Bladder cancer; Renal cancer; Urethral cancer; Urogenital cancer
- Focus Therapeutic Use
- 30 Jan 2018 Planned End Date changed from 10 Aug 2018 to 10 Aug 2019.
- 30 Jan 2018 Planned primary completion date changed from 14 Mar 2018 to 14 Mar 2019.
- 02 Mar 2017 Planned primary completion date changed from 14 Mar 2017 to 14 Mar 2018.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History